Business Wire

NIELSENIQ

9.11.2021 07:03:09 CET | Business Wire | Press release

Share
Brand Extensions Dominate FMCG Innovation in Europe According to NielsenIQ BASES Annual Breakthrough Innovations Report

NielsenIQ BASES is delighted to announce today the launch of its 2021 annual Breakthrough Innovation Report which awards the most successful consumer packaged goods product launches.

The report, which celebrates its 10th anniversary this year, has unveiled the leading innovations of the FMCG world that have made the biggest impact. The brands that made the list reflect a wide range of products and approaches that succeeded in making meaningful connections with consumers, an impressive feat within an increasingly crowded marketplace.

Of the 98 European winners named in the report over the last decade, over 90% percent are still in the market today. When you compare this figure to the regularly used statistic of 90% of new launches failing to survive beyond two years, this demonstrates that NielsenIQ BASES has got its finger on the pulse when it comes to identifying the winning formula for new product launches.

This year's 25 European cross-category winners include representation across multiple markets including UK, France, Germany, Italy, Norway, Russia, Poland, Spain, Switzerland and the Netherlands. This year, these products were overwhelmingly dominated by line extensions, with nearly all of the winners (96%) coming from existing brands. Among the factors defining their success, the winners saw an 86% average value sales increase from Year 1 to Year 2. This is all the more impressive when you consider typically more than half of new products decline in their second year in market.

Celine Grena, European BASES leader, comments: “It is worth noting that when you go back to the first report launched 10 years ago, trends such as ‘shopping locally’, sustainability and convenience were the ‘ones to watch’. While these trends still exist, a number of these are gradually crystallising into the standout theme of mindful living. In fact, over half of the winners this year have at least one mindful living claim, versus only about one quarter in 2019.”

Findings also show that demand for environmentally conscious products is growing and able to drive premiumisation. Consumers are looking for products that use natural ingredients and more sustainable formulations. And whilst it does not have to be the core of the proposition for some brands, waste reduction or a more sustainable production cycle are key trends within the winners.

Alcoholic beverages find success through attracting category buyers to their brand for the first time or opening up new consumption occasions for the brand. In other beverages and food, the focus is on ingredients with added health benefits to support the mind and body. This trend is leading to consumers actively look for low-sugar, -salt, -carb, - calorie and -fat when buying products. This trend is not confined to humans, our beloved pets are also getting products that tap into this demand with ‘free-from’ credentials.

Transparency is another important factor across categories, with clean (64%), locally grown (52%) and ethically sourced (39%) ingredients the top claims that would most impact brand trust. Consumers want to know what they are consuming, where it is coming from and how it impacts their health, so brands will need to put more emphasis on transparency to achieve sales success in the future.

Grena, continues: “Through this year’s winners, we can see that while health and wellness remains an important area of focus, sustainability is increasing in importance within the European market amid growing concerns about climate change. As this trend gathers pace manufacturers will need to respond to this rising social issue through innovative packaging design, and raising awareness of environmentally conscious credentials, to drive impact for new product launches. Premiumisation is another key area we’re seeing develop, both from a packaging and product performance perspectives, with many consumers willing to pay more for these benefits.”

European Winners (listed in alphabetical order):

  • Aspi Gola (Italy)
  • Birds Eye Green Cuisine (UK)
  • Birra Messina Cristalli Di Sale (Italy)
  • Butcher’s Tripe Loaf (UK)
  • Cadbury Darkmilk (UK)
  • Costa Coffee Ready-to-Drink (UK)
  • Febreze Bathroom Air Freshener (UK)
  • Finish Quantum Ultimate (UK & Germany)
  • Hansa Mango IPA (Norway)
  • Hanuta Riegel (Germany)
  • Innocent Plus (UK & France)
  • J.J Whitley – Artisanal Russian Vodka (UK)
  • Leffe d'Été (France)
  • Magnum Vegan (UK & Germany)
  • Martini Fiero (Russia)
  • Pampers Harmonie (France)
  • Persil 4-in-1 discs (Germany)
  • Pringles Rice Fusion (UK)
  • Rimmel Lasting Radiance (UK)
  • Scholl Dry Skin Foot Mask (Germany)
  • Sensodyne Sensitivity & Gum (UK)
  • Somersby Mango i Limonka (Poland)
  • Starbucks for Nespresso (UK, France, Switzerland, Netherlands and Spain)
  • This Isn’t (UK)
  • Whiskas Pure Delight (UK)

ENDS

For further information, please contact Publicasity at NielsenIQ@publicasity.co.uk

About NielsenIQ BASES Breakthrough Innovation

This year’s Breakthrough Innovation process reviewed over 50,000 product launches. The brands that made the 2021 list reflect a wide range of products and approaches that succeeded in making meaningful connections with consumers, an impressive feat within an increasingly crowded marketplace. Beyond BASES requirements for products that reflect strong, distinct qualities such as mass potential, longevity, brand incrementality, category distinction or appeal toward a specific consumer target, this year’s list brings the continued evolution of the success criteria, which includes all six of NielsenIQ BASES’ activation profiles.

About NielsenIQ

NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a groundbreaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.

Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.

NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye